This is a repository copy of *Home Self-Administration of Omalizumab for Chronic Spontaneous Urticaria*.

White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/105950/

Version: Accepted Version

**Article:**

https://doi.org/10.1111/bjd.15074

© 2016 British Association of Dermatologists. Published by Wiley. This is the peer reviewed version of the following article: Denman, S., Ford, K., Toolan, J., Mistry, A., Corps, C., Wood, P. and Savic, S. (2016), Home Self-Administration of Omalizumab for Chronic Spontaneous Urticaria. Br J Dermatol. Accepted Author Manuscript, which has been published at http://dx.doi.org/10.1111/bjd.15074. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving. Uploaded in accordance with the publisher’s self-archiving policy.

**Reuse**
Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher’s website.

**Takedown**
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
Home Self-Administration of Omalizumab for Chronic Spontaneous Urticaria

Sarah Denman, MPharm\textsuperscript{a}, Kate Ford\textsuperscript{a}, John Toolan\textsuperscript{a}, Anoop Mistry, MD\textsuperscript{a}, Claire Corps, PhD\textsuperscript{a}, Philip Wood, PhD\textsuperscript{a}, Sinisa Savic, PhD\textsuperscript{a,b}\textsuperscript{*}

\textsuperscript{a}Department of Clinical Immunology and Allergy, St James's University Hospital, Beckett Street, Leeds, UK

\textsuperscript{b}National Institute for Health Research–Leeds Musculoskeletal Biomedical Research Unit (NIHR-LMBRU) and Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), Wellcome Trust Brenner Building, St James’s University Hospital, Beckett Street, Leeds, UK

\textsuperscript{*}Corresponding author:
Sinisa Savic MD, PhD Department of Clinical Immunology and Allergy, National Institute for Health Research–Leeds Musculoskeletal Biomedical Research Unit (NIHR-LMBRU) and Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), Wellcome Trust Brenner Building, St James University, Beckett Street, Leeds, LS9 7TF, UK
Email:s.savic@leeds.ac.uk Tel: +441132065567, Fax: +441132067250
To the Editor,

Omalizumab is an anti-IgE monoclonal antibody, which is licensed as add-on therapy for chronic spontaneous urticaria (CSU)\(^1\). Although it provides effective symptomatic control, omalizumab does not always induce lasting remission and many patients require repeated courses.

Between August 2010 and July 2016 we treated 123 CSU patients with omalizumab. Only 5% (\(n=6\)) have stopped omalizumab after achieving remission (1.6% [\(n=2\)] after one course only). Of our current cohort, 75% have had >1 treatment course.

Due to perceived risk of anaphylaxis it is recommended that omalizumab is administered by a healthcare professional and treatment for anaphylaxis be available\(^1\). However, the reported prevalence of anaphylaxis in omalizumab treated asthma patients is very low (0.1%)\(^1\). Within CSU patients, none of the 3 pivotal trials reported omalizumab-induced anaphylaxis\(^2,3,4\). There have been few cases reports subsequently and in these it is hard to determine if true anaphylaxis or a CSU flare. Up to July 2016 we have administered 1880 doses of omalizumab to CSU patients and had no reported cases of treatment-associated anaphylaxis.

The increasing number of patients requiring repeated courses of omalizumab for CSU put significant pressure on our nursing capacity. Considering the low-reported prevalence of anaphylaxis, our own experience and patient preference we proposed a home treatment pathway. Our pharmacy risk management group approved this proposal. This treatment pathway can be seen in Figure 1.

Specific patient consent and competency assessment paperwork have been designed and all patients are trained and supplied with adrenaline auto-injectors.

We have a current active cohort of 97 patients and the longest treatment period is 70 months. There are 70% (\(n=68\)) on home treatment. Duration of home treatment ranges from 1 to 19 months (average 7 months, median 7 months). The number of doses administered in hospital before transfer to home ranges from 2 to 45 (average 11; median 7).

There have been no cases of anaphylaxis or other serious adverse effects in those patients treated at home and no patient on home treatment has subsequently transferred back to hospital. Patients report a preference to home treatment as it has a lower impact on their daily living, which subsequently has a positive impact on their quality of life. Adherence (self-reported) in home treatment patients appears to be excellent.

In conclusion, home treatment of omalizumab is a safe, cost-effective pathway that is preferred by patients and increases capacity to provide this treatment for a growing number of patients.
References:


**Figure 1: The Leeds Teaching Hospitals NHS Trust Protocol for Omalizumab for Chronic Spontaneous Urticaria**